New research suggests that medications originally developed for diabetes and obesity could have potential benefits for mental health and cognitive disorders.
A study from the University of Oxford, published in Nature Mental Health, explored how drugs like semaglutide (commonly known as Ozempic and Wegovy) might help treat conditions such as dementia, addiction, depression, and anxiety.
How these drugs might help
The researchers conducted a detailed review of both laboratory studies and clinical research to examine the effects of a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs).
These medications are commonly used to control blood sugar levels in diabetes and to assist with weight loss in people with obesity. However, scientists are now exploring their potential benefits for mental and cognitive health.
The study found early evidence that GLP-1RAs could:
- Improve cognitive function, which may be helpful in dementia.
- Reduce addictive behaviors, which could be useful for substance use disorders.
- Alleviate symptoms of mood and anxiety disorders.
The Need for More Research
Although these findings are promising, the researchers emphasize that more studies are needed to confirm the benefits of these drugs in treating mental health conditions. Most of the available research so far comes from small studies or early-stage clinical trials. To fully understand their effects, large-scale, well-designed trials are necessary.
Dr. Riccardo De Giorgi, a clinical lecturer at the University of Oxford, explained, “Our study brings together the most comprehensive summary of evidence so far on the potential role of GLP-1RAs in conditions like dementia, addiction, and mood disorders. We hope future research can build on this knowledge.”
Since these drugs are already approved for diabetes and obesity, their potential use in mental health could open up new treatment options. However, at this stage, there are no official recommendations for prescribing them for psychiatric conditions.
In the future, doctors from different medical fields—including endocrinologists, psychiatrists, and neuroscientists—may collaborate to explore integrated treatment approaches.
If further research confirms the benefits of GLP-1RAs for mental health, these drugs could provide new hope for patients struggling with conditions that currently have limited treatment options.
The research findings can be found in Nature Mental Health.
Copyright © 2025 Knowridge Science Report. All rights reserved.
